Fortress Biotech Inc FBIOP

NAS: FBIOP | ISIN: US34960Q2084   14/11/2024
5,080 USD (-0,90%)
(-0,90%)   14/11/2024

6 december 2023 · Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics · Persbericht

14 oktober 2021 · Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition · Persbericht

26 februari 2021 · Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® · Persbericht

23 januari 2021 · FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action - FBIO · Persbericht

22 januari 2021 · INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

9 januari 2021 · ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important January 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - FBIO · Persbericht

5 januari 2021 · Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences · Persbericht

3 januari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline - FBIO · Persbericht

Mijn selecties